MAP1LC3A and chronic kidney disease: While we could not find evidence for these mechanisms by immunohistochemistry, their role in CKD-induced microvascular rarefaction cannot be ruled out, since the temporary footprints of these processes (caspase-3, LC-3) may be missed [36, 37].